stacking retatrutide and semaglutide vs Tirzepatide: Best Triple Agonist Guide 2026 Retatrutide vs Tirzepatide vs Semaglutide

Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP

For researchers considering this approach, understanding how much retatrutide to take during maintenance is critical

Clinical trial design matters enormously

The trial is a randomized, double-blind, placebo-controlled multicenter study to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy

Researchers Analyzed Real-World Patient Outcomes The team used Optum Market Clarity, a US electronic health record and insurance claims database, to analyze patients who started liraglutide, semaglutide, or tirzepatide between January 2021 and June 2024

This retatrutide peptide is engineered to act on three major signaling systems: GIP, GLP-1, and glucagon